ArticleScientific reports2014
Producing aglycons of ginsenosides in bakers' yeast.
Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 155 citations in OpenAlex.
- Diverse oxidosqualene cyclases for triterpenoid biosynthesis.Synthetic and systems biotechnology · 2027Review
- Modular reconstruction and multilevel regulation ofSynthetic and systems biotechnology · 2026Article
- Advances in the heterologous biosynthesis of QS saponins: a review.Microbial cell factories · 2026Review
- Sustainable Production of Ginsenosides: Advances in Biosynthesis and Metabolic Engineering.Plants (Basel, Switzerland) · 2025Review
- Calcium-Induced Regulation ofJournal of fungi (Basel, Switzerland) · 2025Article
- Engineering Saccharomyces cerevisiae for medical applications.Microbial cell factories · 2025Review
- A Novel Biosynthetic Strategy for Ginsenoside Ro: Construction of a Metabolically EngineeredInternational journal of molecular sciences · 2024Article
- Advances in the Structures, Pharmacological Activities, and Biosynthesis of Plant Diterpenoids.Journal of microbiology and biotechnology · 2024Review
- Review
- Biosynthetic pathway of prescription cucurbitacin IIa and high-level production of key triterpenoid intermediates in engineered yeast and tobacco.Plant communications · 2024Article
- Two-Phase Fermentation Systems for Microbial Production of Plant-Derived Terpenes.Molecules (Basel, Switzerland) · 2024Review
- Transcriptome-Wide Identification and Integrated Analysis of aPlants (Basel, Switzerland) · 2024Article
- Engineering amino acid residues of pentacyclic triterpene synthases for improving the activity.Applied microbiology and biotechnology · 2024Article
- When synthetic biology meets medicine.Life medicine · 2024Review
- Application and development of CRISPR technology in the secondary metabolic pathway of the active ingredients of phytopharmaceuticals.Frontiers in plant science · 2024Review
- Compound K Production: Achievements and Perspectives.Life (Basel, Switzerland) · 2023Review
- Advances in the biosynthesis and metabolic engineering of rare ginsenosides.Applied microbiology and biotechnology · 2023Review
- Current advances for omics-guided process optimization of microbial manufacturing.Bioresources and bioprocessing · 2023Review
- Production of a Novel Protopanaxatriol-Type Ginsenoside by Yeast Cell Factories.Bioengineering (Basel, Switzerland) · 2023Article
- Heterologous Expression of the Hot Pepper ABA 8'-Hydroxylase inJournal of microbiology and biotechnology · 2023Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ginsenosides are the primary bioactive components of ginseng, which is a popular medicinal plant that exhibits diverse pharmacological activities. Protopanaxadiol, protopanaxatriol and oleanolic acid are three basic aglycons of ginsenosides. Producing aglycons of ginsenosides in Saccharomyces cerevisiae was realized in this work and provides an alternative route compared to traditional extraction methods. Synthetic pathways of these three aglycons were constructed in S. cerevisiae by introducing β-amyrin synthase, oleanolic acid synthase, dammarenediol-II synthase, protopanaxadiol synthase, protopanaxatriol synthase and NADPH-cytochrome P450 reductase from different plants. In addition, a truncated 3-hydroxy-3-methylglutaryl-CoA reductase, squalene synthase and 2,3-oxidosqualene synthase genes were overexpressed to increase the precursor supply for improving aglycon production. Strain GY-1 was obtained, which produced 17.2 mg/L protopanaxadiol, 15.9 mg/L protopanaxatriol and 21.4 mg/L oleanolic acid. The yeast strains engineered in this work can serve as the basis for creating an alternative way for producing ginsenosides in place of extractions from plant sources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.